




The relative strengths and weaknesses of Enanta Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Enanta Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 133% points. The greatest weakness of Enanta Pharmaceuticals INC is the variable Intangible Assets, reducing the Economic Capital Ratio by 2.8% points.

The company's Economic Capital Ratio, given in the ranking table, is 427%, being 176% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	237,819
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	20,982
Liabilities, Non-Current	2,410
Other Assets	80,769
Other Compr. Net Income	-131
Other Expenses	9,237
Other Liabilities	1,569
Other Net Income	2,333
Other Revenues	102,814
Property and Equipment	8,049
Research and Development	57,451
Selling, General and Administrative Expense	20,749

Output Variable	Value in 1000 USD
Assets	326,637
Liabilities	24,961
Expenses	87,437
Revenues	102,814
Stockholders Equity	301,676
Net Income	17,710
Comprehensive Net Income	17,644
BaseVar	272,156
ECR before Limited Liability	384%
Economic Capital Ratio	427%